Cabozantinib in Advanced Renal Cell Carcinoma: Is it a METEOR?

Ciccarese, Chiara; Massari, Francesco

doi:10.1016/j.eururo.2015.12.030

Cited by 3 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The available data show hints that there may be specific subpopulations of patients with advanced RCC or mRCC who are more likely to benefit from cabozantinib [Ciccarese et al . 2015].…”

Section: Bone Metastasesmentioning

confidence: 99%

“…The available data show hints that there may be specific subpopulations of patients with advanced RCC or mRCC who are more likely to benefit from cabozantinib [Ciccarese et al 2015]. Bone metastases depend on complex interactions between tumor cells, osteoblasts, and osteoclasts, and they can occur in almost 35% of patients with advanced RCC or mRCC [Woodward et al 2011].…”

Section: Bone Metastasesmentioning

confidence: 99%

See 1 more Smart Citation

Cabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience

Ruíz-Morales

Heng

2016

Therapeutic Advances in Urology

View full text Add to dashboard Cite

Abstract:The treatment of metastatic renal cell carcinoma (mRCC) is rapidly changing. During first-line treatment with targeted therapy, patients ultimately develop resistance to therapy and the disease progresses. Recently, cabozantinib has demonstrated a better response rate, progression-free survival and overall survival compared with everolimus after failure of prior targeted therapy in patients with advanced or metastatic renal cell carcinoma (RCC). Cabozantinib is a small-molecule tyrosine kinase inhibitor (TKI). It exerts inhibition of MET, vascular endothelial growth factor receptor type 2, AXL, and many other receptor tyrosine kinases that are also implicated in tumor pathobiology, including RET, KIT, and FLT3. MET drives tumor survival, invasion, angiogenesis, and metastasis through several downstream signaling pathways. AXL has recently been described as an essential mediator of cancer metastasis that mediates crosstalk and resistance to TKIs. MET and AXL are thought to be anti-vascular endothelial growth factor receptor (VEGF) resistance pathways and thus cabozantinib represents a logical choice after progression on initial VEGF therapy. Subgroup analyses examining those with good performance status or visceral and bone metastases indicate that the hazard ratios may be better when using cabozantinib versus everolimus. However, there were no clear statistically significant differences between any subgroups.

show abstract

“…The available data show hints that there may be specific subpopulations of patients with advanced RCC or mRCC who are more likely to benefit from cabozantinib [Ciccarese et al . 2015].…”

Section: Bone Metastasesmentioning

confidence: 99%

Section: Bone Metastasesmentioning

confidence: 99%

Cabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience

Ruíz-Morales

Heng

2016

Therapeutic Advances in Urology

View full text Add to dashboard Cite

show abstract

The role of the MET/AXL pathway as a new target for multikinase inhibitors in renal cell carcinoma

Nunno

Cubelli

Massari

2017

Expert Review of Precision Medicine and Drug Development

View full text Add to dashboard Cite

Repositioning Bevacizumab: A Promising Therapeutic Strategy for Cartilage Regeneration

Lee

Nemeno

Lee

2016

Tissue Engineering Part B: Reviews

View full text Add to dashboard Cite

Drug discovery and development has been garnering an increasing trend of research due to the growing incidence of the diverse types of diseases. Recently, drug repositioning, also known as drug repurposing, has been emerging parallel to cancer and tissue engineering studies. Drug repositioning involves the application of currently approved or even abandoned drugs as alternative treatments to other diseases or as biomaterials in other fields including cell therapy and tissue engineering. In this review, the advancement of the antiangiogenesis drugs that were used as treatment for cancer and other diseases, with particular focus on bevacizumab, will be described. This will include an overview of the nature and progression of osteoarthritis (OA), one of the leading global degenerative diseases that cause morbidity, and the development of its therapeutic strategies. In addition, this will also feature the nonsteroidal anti-inflammatory drugs that are commonly prescribed for OA and the benefits of repositioning bevacizumab as alternative treatments for other diseases and as biomaterials for cartilage regeneration. To date, a few number of studies, employing different modes of administration and varying dosages in diverse animal models, have shown that bevacizumab can be used as a signal and can promote both in vitro and in vivo cartilage regeneration. However, other antiangiogenesis drugs and their effects in chondrogenesis and cartilage regeneration are also worth investigating.

show abstract

Cabozantinib in Advanced Renal Cell Carcinoma: Is it a METEOR?

Cited by 3 publications

References 5 publications

Cabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience

Cabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience

The role of the MET/AXL pathway as a new target for multikinase inhibitors in renal cell carcinoma

Repositioning Bevacizumab: A Promising Therapeutic Strategy for Cartilage Regeneration

Contact Info

Product

Resources

About